This also helps explain our findings that the effect of the recombinant peptide of SPARC's N-terminus domain on tumor regression was superior to SPARC: in addition to enhancing apoptosis in response to 5-FU, it also reduced the rate of tumor growth by ∼ 40% in comparison to SPARC-over-expressing tumors. Here, SPARC is linked to neoplasm.